Literature DB >> 15853678

Neuroprotection and regeneration strategies for spinal cord repair.

Eve C Tsai1, Charles H Tator.   

Abstract

The journey toward a cure for spinal cord injury (SCI) has taken many paths. In this article, we review these paths, and highlight the clinical applications of these experimental repair strategies. Initial strategies involved attempts at neuroprotection with steroids and other anti-inflammatory drugs. Other anti-ischemia treatments, agents to eliminate the damage from excitotoxicity, and anti-apoptotic agents were also tried. Another avenue involved enhancing the function of the remaining uninjured axons by measures to produce remyelination and medications to improve axonal conduction. In the last two decades there has been a major effort to enhance spinal cord axonal regeneration through a variety of techniques including neutralization of neurite inhibition, administration of neurotrophic factors, implantation of synthetic channels, and transplantation of a variety of cell types. Indeed, several of these strategies have been so promising in animals that clinicians have been stimulated to explore their potential human application. We also examine the different experimental models of SCI used to assess repair, and discuss how the injury model impacts on the assessment of axonal regeneration and functional recovery after SCI. The mechanisms of recovery that may be involved after SCI will be analyzed, and their relevance toward finding a cure for human SCI. Unfortunately, the goal of producing significant functional regeneration of the human spinal cord has not yet been achieved despite the many strategies that have been developed. It is our hope that improved understanding of the mechanisms underlying functional recovery will lead to successful therapeutic strategies in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853678     DOI: 10.2174/1381612053507404

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

1.  Nanoparticle Estrogen in Rat Spinal Cord Injury Elicits Rapid Anti-Inflammatory Effects in Plasma, Cerebrospinal Fluid, and Tissue.

Authors:  April Cox; Abhay Varma; John Barry; Alexey Vertegel; Naren Banik
Journal:  J Neurotrauma       Date:  2015-06-25       Impact factor: 5.269

2.  Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma.

Authors:  Fei Qiao; Carl Atkinson; Hongbin Song; Ravinder Pannu; Inderjit Singh; Stephen Tomlinson
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury.

Authors:  Fei Qiao; Carl Atkinson; Mark S Kindy; Anandakumar Shunmugavel; B Paul Morgan; Hongbin Song; Stephen Tomlinson
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

Review 4.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012

5.  Developmental regulation of metabotropic glutamate receptor 1 splice variants in olfactory bulb mitral cells.

Authors:  P Bovolin; S Bovetti; A Fasolo; Z Katarova; G Szabo; M T Shipley; F L Margolis; A C Puche
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

Review 6.  Recent advances in the pharmacologic treatment of spinal cord injury.

Authors:  April Cox; Abhay Varma; Naren Banik
Journal:  Metab Brain Dis       Date:  2014-05-16       Impact factor: 3.584

Review 7.  Anesthetic considerations for patients with acute cervical spinal cord injury.

Authors:  Fang-Ping Bao; Hong-Gang Zhang; Sheng-Mei Zhu
Journal:  Neural Regen Res       Date:  2017-03       Impact factor: 5.135

Review 8.  Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Authors:  Sarah M Carpanini; Megan Torvell; Bryan Paul Morgan
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.